Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Financing Activities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Cash from Financing Activities for 14 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 46.01% year-over-year to $1.7 million, compared with a TTM value of $5.5 million through Dec 2025, down 94.5%, and an annual FY2025 reading of $5.5 million, down 94.5% over the prior year.
  • Cash from Financing Activities was $1.7 million for Q4 2025 at Fate Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $438.0 million in Q1 2021 and bottomed at -$180000.0 in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $33.4 million, with a median of $2.5 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities crashed 111.87% in 2023, then soared 46029.47% in 2024.
  • Year by year, Cash from Financing Activities stood at $3.4 million in 2021, then tumbled by 55.62% to $1.5 million in 2022, then plummeted by 111.87% to -$180000.0 in 2023, then soared by 1838.89% to $3.1 million in 2024, then crashed by 46.01% to $1.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for FATE at $1.7 million in Q4 2025, $2.5 million in Q3 2025, and $1.3 million in Q2 2025.